The Commission has launched COMPASS-AI – a new initiative that includes the establishment of a community of experts to advance the safe and effective use of artificial intelligence (AI) in healthcare. This is one of the flagship measures in the Commission’s recent Apply AI Strategy. The initiative will work to promote the responsible and effective integration …
The Health Security Committee (HSC) met to discuss the upcoming Union prevention, preparedness and response plan for health crises. The Union Plan, which the Commission will present in the coming months, is one of the key actions listed in the Action Plan accompanying the EU Preparedness Union Strategy, as well as a requirement under Article 5 …
The European Commission adopted an implementing regulation establishing the rules for joint clinical assessments of medical devices and in vitro diagnostic medical devices, under the Health Technology Assessment (HTA) Regulation. The implementing act provides detailed procedural rules for the joint clinical assessments, covering: Cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission …
The Commission is inviting input on the Union’s future prevention, preparedness and response plan for health crises, through a Call for Evidence published. The call is open to citizens, public institutions, patient organisations, NGOs, healthcare providers and professionals, research and technology organisations, academia, and other interested parties that wish to give their views. The Union prevention, preparedness …
The European Union has officially launched the Partnership on One Health Antimicrobial Resistance (OHAMR). Co-funded by Horizon Europe with €75 million, this ambitious 10-year programme tackles the urgent global health threat of antimicrobial resistance (AMR). Next steps AMR causes over 35,000 deaths annually in the EU and 1.27 million worldwide (2019), with projections of up to 10 million per …
The European Commission has granted EU marketing authorisation for Kisunla, a medicine to treat mild cognitive impairment, including mild dementia in the early stages of Alzheimer’s disease. Kisunla can help to slow down the progression of cognitive and functional issues associated with Alzheimer’s disease in certain patients. The authorisation is based on the positive scientific assessment …
The European Commission has granted EU marketing authorisation for zuranolone, a medicine to treat postpartum depression (PPD). PPD is a mental health condition that can affect women following childbirth and is marked by persistent sadness, anxiety, fatigue and difficulty functioning. It can be severe and long-lasting, with negative consequences for the mother and child. There …
EMA and the Heads of Medicines Agencies (HMA) are warning the public about the growing threat of illegal medicines being advertised and sold online across the European Union (EU). In recent months there has been a sharp rise in the number of illegal medicines marketed as GLP-1 receptor agonists such as semaglutide, liraglutide and tirzepatide …
The European Commission invites interested stakeholders to share their views on future priorities, orientations and needs for the future by 30th September 2025. This includes Member State authorities responsible for health at national, regional or local level. Engagement with organisations representing patients, civil society, healthcare professionals and healthcare providers, researchers, academia, networks of expertise and business is crucial …
The Commission is inviting input on EU’s future Cardiovascular Health Plan, through a Call for Evidence published. The call is open to citizens, patient organisations, NGOs, healthcare providers and professionals, research and technology organisations, academia, and other interested parties that wish to give their views. Cardiovascular diseases are the number one cause of death in the EU, …